Stay updated on Pembrolizumab in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in EOC Clinical Trial page.

Latest updates to the Pembrolizumab in EOC Clinical Trial page
- Check6 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the page.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedPage revision updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision label updated to v3.4.3 (previously v3.4.2). This appears to be a minor site version change and does not modify study data or content.SummaryDifference0.1%

- Check71 days agoChange DetectedFallopian tube cancer added as a condition and the page updated to version 3.4.2; the government funding status notice has been removed.SummaryDifference0.5%

- Check78 days agoChange DetectedA site-wide government funding/status notice was added and the page version updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check85 days agoChange DetectedAdded a Show glossary control and updated metadata labels, including 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the revision to v3.4.0 (from v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in EOC Clinical Trial page.